BioNTech And Bristol Myers Squibb Partner To Advance Bispecific Antibody BNT327 For Solid Tumors

• BNT327, BioNTech's PD-L1xVEGF-A bispecific antibody, is a clinically advanced investigational immunotherapy candidate with the potential to surpass current checkpoint inhibitor outcomes and set a new standard of care in multiple tumor types
• The co-development and co-commercialization collaboration with a 50/50 profit/loss split will leverage both partners' expertise, resources and global footprint to accelerate BNT327's path towards potential regulatory approvals and market launches
• BioNTech and Bristol Myers Squibb will jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor types

BioNTech SE (NASDAQ:BNTX, "BioNTech"))) and Bristol Myers Squibb (NYSE:BMY, "BMS"))) today announced that the companies have entered into an agreement for the global co-development and co-commercialization of BioNTech's investigational bispecific antibody BNT327 across numerous solid tumor types. Under the agreement, BioNTech and BMS will work jointly to broaden and accelerate the development of this clinical candidate.